Transcatheter Technologies GmbH is expanding its product family to include a transcatheter mitral valve implantation (TMVI) version – Tresillo.
“Per plan, we are expanding our platform technology to comprise a transfemoral and transapical Trinity TAVI system as well as a transfemoral Tresillo mitral valve implantation system. These three systems all share the same features. The pre-mounted, valved stent is folded without the need of an outer sheath, thereby enabling precision controlled positioning and also allowing for repositioning if needed. This feature is most certainly unique to Trinity and Tresillo,” said Wolfgang Goetz, chief executive officer.
The company believes that transcatheter mitral valve implantation is the next frontier for structural heart therapy. Approximately 3% of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from this interventional procedure while avoiding open-heart surgery.
“While we are very pleased with our product development variety and timelines, we are planning to further expand our pipeline of interventional innovations that are designed not only to be simpler to use but also facilitate superior patient safety and outcomes,” added Goetz.
